Download PDF
Zeitschrift für Komplementärmedizin 2013(03): 46-49
DOI: 10.1055/s-0033-1347926
zkm | Wissen
Haug Verlag in MVS Medizinverlage Stuttgart GmbH & Co. KG Stuttgart

Wirkweisen, Vorteile und Anwendung Neuere Antidiabetika

Klaus-Dieter Palitzsch Prof. Dr.
Further Information

Publication History

Publication Date:
03 July 2013 (online)

    Permissions and Reprints

Keywords

Refresher - Antidiabetika - Nüchternblutzucker - postprandialer Blutzucker - HbA1c-Wert - Hypoglykämie
 

  • Literatur

  • 1 Seck T, Nauck M, Sheng D et al. Safety and efficacy of treatment with sitagliptin or glipizide in patients with type 2 diabetes inadequately controlled on metformin: a 2-year study.. Int J Clin Pract 2010; 64: 562-576
    CrossrefGoogle Scholar
  • 2 Charbonnel B, Karasik A, Liu J et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone.. Diabetes Care 2006; 29: 2638-2643
    CrossrefPubMedGoogle Scholar
  • 3 Amori RE, Lau J, Pittas AG. Efficacy and safety of incretin therapy in type 2 diabetes. systematic review and meta-analysis. JAMA 2007; 298: 194-206
    CrossrefPubMedGoogle Scholar
  • 4 Astrup A, Rössner S, Van Gaal L et al. Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study.. Lancet 2009; 374: 1606-1616
    CrossrefGoogle Scholar
  • 5 Buse JB, Rosenstock J, Sesti G et al. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6).. Lancet 2009; 374: 39-47
    CrossrefGoogle Scholar
  • 6 Buse JB, Drucker DJ, Taylor KL et al. DURATION-1: Exenatide once weekly produces sustained glycemic control and weight loss over 52 weeks.. Diabetes Care 2010; 33: 1255-1261
    CrossrefGoogle Scholar
  • 7 Bergenstal RM, Wysham C, MacConell L et al. Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial.. Lancet 2010; 376: 431-439
    CrossrefPubMedGoogle Scholar
  • 8 Parks M, Rosebraugh C. Weighing Risks and Benefits of Liraglutide – The FDA's review of a new antidiabetic therapy.. N Engl J Med 2010; 362: 774-777
    CrossrefGoogle Scholar
  • 9 Turner RC, Cull CA, Frighi V et al. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group.. JAMA 1999; 281: 2005-2012
    CrossrefPubMedGoogle Scholar